Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update
September 29, 2020 07:00 ET
|
Mereo BioPharma Group plc
On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020 Enrolment resumed in Phase 2 study of alvelestat in Alpha-1 Antitrypsin Deficiency and initiated...
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta
September 24, 2020 07:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused...
Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2020 and Host Conference Call on September 29, 2020
September 16, 2020 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused...
Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease
August 25, 2020 07:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on...
Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development
June 30, 2020 07:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on...
Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019
June 16, 2020 07:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on...
Mereo BioPharma Announces Completion of $70 Million Private Placement
June 04, 2020 07:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) today announces the completion of a $70 million (£56 million) private placement...
Business Update and Directorate Change
March 27, 2020 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., March 27, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on...
Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
February 28, 2020 07:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on...
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
February 19, 2020 03:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it has entered into a Securities...